 The redirector trial is the first clinical study in which two-by-specific monoclonal antibodies, in this case Teclistamabana-Talquetamaba, had been combined and evaluated in a cohort of patients with relaxant refractory multiple myeloma. Teclistamaba targets BCMA, Talquetamaba targets GPR-C5D, and the hypothesis is to combine two-by-specific monoclonal antibodies will have a synergistic effect. In addition, in this study, there is a specific cohort of patients with pure extramedulary disease. The efficacy data are very relevant because 93 patients have been included across all those levels and 34 patients received the recommended phase 2 dose, 3 milligrams per kilo for Teclistamaba, 0.8 milligrams per kilo for Talquetamaba, every other week. And overall, the overall response rate is approximately 85% and reached 95% at the recommended phase 2 dose. And important to note that the complete response rate is approximately 40%. The median durability of the response has not been reached yet. Responses are quite rapid and the best response is achieved within the first three, four cycles. And the median progression of survival has been reached across all those levels and it is 20 months, but it has not been reached yet in the population receiving the recommended phase 2 dose. But also important to note that in this group of patients with extramedulary disease, the efficacy is maintained with an overall response rate of almost 80%. And this is relevant because where this combination can represent a fair choice for these patients with extramedulary disease. Safety profile is crucial and indeed this was the primary objective of this clinical study. And in principle, the safety profile is acceptable and it is consistent with the safety profile so far reported for Talquetamaba single agent and Teclistamaba single agent. From the hematological point of view, neutropenia is the most frequent grade 3, 4 adverse event reported in approximately 60% of the patients. What is true that the incidence of fibrile neutropenia is quite low and it doesn't reach 9% at the recommended phase 2 dose. From the non-hematological point of view, cytokine release syndrome is the most frequent non-hematological adverse event. But it is the grade 1 and 2 in majority of the patients are resolved with supportive care. ICANN's events are not very frequent and only three patients develop five ICANN's events. We have to consider also other toxicity related with Talquetamaba because of the targeted GPR-C5D and we've observed this geosia, skin abnormalities, nails abnormalities in approximately 50% of the patients but in all patients it was grade 1 and 2 and resolved. And concerning infections that may be the critical adverse event in relation with the bi-specific monoclonal antibodies, the combination of Teclistamaba and Talquetamaba did not result in more infections and although overall 80% of the patients develop any type of infections, the incidence of grade 3-4 infection is comparable to that reported with the Teclistamaba single agent. Well, for patients I think that the predirect trial represents a new opportunity in this case to combine two bi-specific monoclonal antibodies. And the key question is from my point of view and especially for the patients, is it better to receive both together or is it possible to receive one and the second one later on? And both answers are possible, but I would say that the combination of these two bi-specific monoclonal antibodies results in a higher efficacy than for the bi-specific monoclonal antibodies single agent, we need a longer follow-up in order to see the progression of survival, but again seems to be longer. And I would like to emphasize the efficacy of this combination in patients with extramedular disease. Patients when they do present extramedular disease, pure extramedular disease, plasma cytomas in the liver, in the pantheas, in the pericardial, or even in the schema, we know that these are challenging situations, so we are going to expand a specific cohort of patients with extramedular disease in order to evaluate in more detail this combination and this will be a great opportunity for patients with a pure extramedular disease.